Titan Partners Group, a division of American Capital Partners LLC (“Titan Partners”), today announced that Dr. David Sans has joined the firm as head of healthcare. Dr. Sans will lead the team that covers companies in the biopharmaceuticals, diagnostics, medtech and specialty pharmaceuticals sectors. “We are excited to bring in David Sans to join Titan Partners and lead our healthcare practice as we continue to expand our footprint and capacity in this sector,” said Michael Sands, Titan Partners co-founder and partner. “David’s expertise in life sciences makes him a valuable addition to our team. Titan Partners is committed to building out a leading healthcare division. His experience and knowledge set us apart from our competitors, which perfectly complements our existing capabilities.”
To view the full press release, visit https://ibn.fm/4RCTi
About Titan Partners Group LLC
Titan Partners Group, a division of American Capital Partners LLC, is a boutique investment bank founded by experienced financial services experts. The company’s team of leading securities professionals provides a suite of bespoke services to emerging growth companies and their investors. Titan Partners’ founding principle is to set the standard for securities transactions in the lower middle market. Titan Partners’ vision and forward-thinking approach keep it ahead of the ever-changing landscape and constantly challenge the “status quo.” The company prides itself on the trust built through its client-centric approach and ability to deliver on its promises.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.